This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.48% per year. These returns cover a period from January 1, 1988 through May 5, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ETFs to Capitalize on the Novo Nordisk-Septerna Deal
by Sweta Killa
Novo Nordisk announces a $2.2 billion deal with Septerna to tap the growing obesity treatment market.
Eli Lilly Cuts Q4 Sales Forecast: ETFs to Buy on the Dip
by Sweta Killa
Eli Lilly slashes the revenue guidance for the fourth quarter and fiscal 2024 but offers a bullish outlook for 2025.
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, PPH, HRTS and THNR
by Zacks Equity Research
Eli Lilly, Novo Nordisk, PPH, HRTS and THNR are part of the Zacks top Analyst Blog.
Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win
by Sanghamitra Saha
In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications.
Tap the Weight-Loss Drug Market With These ETFs
by Sweta Killa
Investors seeking to tap the boom in weight-loss drug treatment could consider these ETFs.
5 ETFs to Make the Most of Eli Lilly's Strength
by Sweta Killa
Impressed by Eli Lilly's (LLY) blowout earnings, several analysts raised their target price on the stock.
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment
by Sanghamitra Saha
Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), have so far dominated the weight-loss drug market. Now, Roche recently announced encouraging Phase I trial data for its new obesity drug candidate.
Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?
by Sanghamitra Saha
On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.
ETFs to Profit from the Weight Loss Drug Boom
by Neena Mishra
The market for GLP-1 drugs could soar to $130 billion by 2030